Logo

Genomind Genecept Assay

Jan 20, 2016

Genomind has launched a new, expanded version of its Genecept Assay, a pharmacogenetic test to help guide psychiatric treatment. The company has added eight more genes to its existing panel of 10, based on a meta-analysis of hundreds of published studies showing that variations in these genes can inform decisions for psychiatric treatment. The test now covers chronic pain and substance abuse, as well as depression, anxiety, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, bipolar disorder, post-traumatic stress disorder, autism and schizophrenia. It also covers more than 15 drug classes, 103 FDA-approved medications, and 97 percent of drugs used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder, autism, and pain disorders.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.